company background image

Sandu Pharmaceuticals BSE:524703 Stock Report

Last Price


Market Cap







16 Aug, 2022


Company Financials
524703 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance5/6
Financial Health6/6

524703 Stock Overview

Sandu Pharmaceuticals Limited manufactures and markets ayurvedic medicines under the SANDU brand in India.

Sandu Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sandu Pharmaceuticals
Historical stock prices
Current Share Price₹69.10
52 Week High₹86.00
52 Week Low₹43.35
1 Month Change6.31%
3 Month Change-7.81%
1 Year Change21.23%
3 Year Change383.22%
5 Year Change173.66%
Change since IPO821.33%

Recent News & Updates

Shareholder Returns

524703IN Personal ProductsIN Market

Return vs Industry: 524703 exceeded the Indian Personal Products industry which returned 2.3% over the past year.

Return vs Market: 524703 exceeded the Indian Market which returned 8.3% over the past year.

Price Volatility

Is 524703's price volatile compared to industry and market?
524703 volatility
524703 Average Weekly Movement5.6%
Personal Products Industry Average Movement4.2%
Market Average Movement6.4%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.1%

Stable Share Price: 524703 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 524703's weekly volatility (6%) has been stable over the past year.

About the Company

1899309Umesh Sandu

Sandu Pharmaceuticals Limited manufactures and markets ayurvedic medicines under the SANDU brand in India. The company offers medicines in the areas of respiratory; women’s and men’s; digestive; muscular and bone; urinary; hair and skin; child; nerve and memory; heart and blood; metabolism and immunity; gold products; personal hygiene; and immunity boosters. Sandu Pharmaceuticals Limited was founded in 1899 and is based in Mumbai, India.

Sandu Pharmaceuticals Fundamentals Summary

How do Sandu Pharmaceuticals's earnings and revenue compare to its market cap?
524703 fundamental statistics
Market Cap₹667.57m
Earnings (TTM)₹15.90m
Revenue (TTM)₹655.01m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524703 income statement (TTM)
Cost of Revenue₹357.43m
Gross Profit₹297.58m
Other Expenses₹281.68m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)1.65
Gross Margin45.43%
Net Profit Margin2.43%
Debt/Equity Ratio0.0%

How did 524703 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does 524703 pay a reliable dividends?

See 524703 dividend history and benchmarks
When do you need to buy 524703 by to receive an upcoming dividend?
Sandu Pharmaceuticals dividend dates
Ex Dividend DateSep 22 2022
Dividend Pay DateOct 30 2022
Days until Ex dividend36 days
Days until Dividend pay date74 days

Does 524703 pay a reliable dividends?

See 524703 dividend history and benchmarks
We’ve recently updated our valuation analysis.


Is 524703 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524703?

Other financial metrics that can be useful for relative valuation.

524703 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1x
Enterprise Value/EBITDA21.8x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 524703's PE Ratio compare to its peers?

524703 PE Ratio vs Peers
The above table shows the PE ratio for 524703 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average90x
542248 Deccan Health Care
531412 Radix Industries (India)
530689 Lykis
WALPAR Walpar Nutritions
524703 Sandu Pharmaceuticals

Price-To-Earnings vs Peers: 524703 is good value based on its Price-To-Earnings Ratio (42x) compared to the peer average (90x).

Price to Earnings Ratio vs Industry

How does 524703's PE Ratio compare vs other companies in the Asian Personal Products Industry?

Price-To-Earnings vs Industry: 524703 is good value based on its Price-To-Earnings Ratio (42x) compared to the Indian Personal Products industry average (60.3x)

Price to Earnings Ratio vs Fair Ratio

What is 524703's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524703 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524703's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 524703 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524703 (₹69.1) is trading above our estimate of fair value (₹4.38)

Significantly Below Fair Value: 524703 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Sandu Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sandu Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Past Performance

How has Sandu Pharmaceuticals performed over the past 5 years?

Past Performance Score


Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524703 has high quality earnings.

Growing Profit Margin: 524703's current net profit margins (2.4%) are higher than last year (1.9%).

Past Earnings Growth Analysis

Earnings Trend: 524703 has become profitable over the past 5 years, growing earnings by 36.3% per year.

Accelerating Growth: 524703's earnings growth over the past year (45.5%) exceeds its 5-year average (36.3% per year).

Earnings vs Industry: 524703 earnings growth over the past year (45.5%) exceeded the Personal Products industry -1.4%.

Return on Equity

High ROE: 524703's Return on Equity (4.4%) is considered low.

Discover strong past performing companies

Financial Health

How is Sandu Pharmaceuticals's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524703's short term assets (₹236.5M) exceed its short term liabilities (₹118.7M).

Long Term Liabilities: 524703's short term assets (₹236.5M) exceed its long term liabilities (₹9.4M).

Debt to Equity History and Analysis

Debt Level: 524703 is debt free.

Reducing Debt: 524703 has no debt compared to 5 years ago when its debt to equity ratio was 38.6%.

Debt Coverage: 524703 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 524703 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Sandu Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayAug 16 2022Ex Dividend DateSep 22 2022Dividend Pay DateOct 30 202238 days from Ex DividendBuy in the next 36 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 524703's dividend (0.72%) is higher than the bottom 25% of dividend payers in the Indian market (0.39%).

High Dividend: 524703's dividend (0.72%) is low compared to the top 25% of dividend payers in the Indian market (1.7%).

Stability and Growth of Payments

Stable Dividend: Too early to tell whether 524703's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 524703's dividend payments are increasing as they only just started paying a dividend.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (25.1%), 524703's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (448.4%), 524703's dividend payments are not well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Umesh Sandu (55 yo)





Mr. Umesh Bhaskar Sandu serves as the Managing Director and Executive Director of Sandu Pharmaceuticals Limited since June 2, 2018 and served as its Company Secretary.

CEO Compensation Analysis

Compensation vs Market: Umesh's total compensation ($USD45.70K) is about average for companies of similar size in the Indian market ($USD37.68K).

Compensation vs Earnings: Umesh's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: 524703's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Experienced Board: 524703's board of directors are seasoned and experienced ( 11.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22%.

Top Shareholders

Company Information

Sandu Pharmaceuticals Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Sandu Pharmaceuticals Limited
  • Ticker: 524703
  • Exchange: BSE
  • Founded: 1899
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: ₹667.574m
  • Shares outstanding: 9.66m
  • Website:

Number of Employees


  • Sandu Pharmaceuticals Limited
  • Sandu Nagar
  • D.K. Sandu Marg
  • Mumbai
  • Maharashtra
  • 400071
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.